Your browser doesn't support javascript.
loading
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.
Ji, Jiuping; Zhang, Yiping; Redon, Christophe E; Reinhold, William C; Chen, Alice P; Fogli, Laura K; Holbeck, Susan L; Parchment, Ralph E; Hollingshead, Melinda; Tomaszewski, Joseph E; Dudon, Quentin; Pommier, Yves; Doroshow, James H; Bonner, William M.
Afiliação
  • Ji J; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Zhang Y; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Redon CE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Reinhold WC; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Fogli LK; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Holbeck SL; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Parchment RE; Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
  • Hollingshead M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Tomaszewski JE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Dudon Q; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Pommier Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Doroshow JH; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Bonner WM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States of America.
PLoS One ; 12(2): e0171582, 2017.
Article em En | MEDLINE | ID: mdl-28158293
ABSTRACT
Phosphorylated H2AX (γ-H2AX) is a sensitive marker for DNA double-strand breaks (DSBs), but the variability of H2AX expression in different cell and tissue types makes it difficult to interpret the meaning of the γ-H2AX level. Furthermore, the assays commonly used for γ-H2AX detection utilize laborious and low-throughput microscopy-based methods. We describe here an ELISA assay that measures both phosphorylated H2AX and total H2AX absolute amounts to determine the percentage of γ-H2AX, providing a normalized value representative of the amount of DNA damage. We demonstrate the utility of the assay to measure DSBs introduced by either ionizing radiation or DNA-damaging agents in cultured cells and in xenograft models. Furthermore, utilizing the NCI-60 cancer cell line panel, we show a correlation between the basal fraction of γ-H2AX and cellular mutation levels. This additional application highlights the ability of the assay to measure γ-H2AX levels in many extracts at once, making it possible to correlate findings with other cellular characteristics. Overall, the γ-H2AX ELISA represents a novel approach to quantifying DNA damage, which may lead to a better understanding of mutagenic pathways in cancer and provide a useful biomarker for monitoring the effectiveness of DNA-damaging anticancer agents.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosforilação / Bioensaio / Dano ao DNA / Histonas Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosforilação / Bioensaio / Dano ao DNA / Histonas Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos